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Abstract Cytosolic glyoxalase II from Arabidopsis thaliana, 
GLX2-2, was overexpressed and purified to homogeneity using 
Q-sepharose chromatography. MALDI-TOF mass spectrometry 
studies indicated a molecular weight of 28 767 Da. Using steady-
state kinetics studies, the purified enzyme exhibited a Km of 
660 ± 100 (iM and a Acat of 484 ± 92 s"
1 at 37°C. Metal analyses 
demonstrated that the enzyme binds 2.1 ± 0.5 moles of Zn(II) per 
monomer; the binding of Zn(II) is essential for enzyme viability 
and activity. Sequence comparison of glyoxalase II enzymes 
from human, A. thaliana, and yeast and the metallo-p-
lactamases reveal that all metal binding ligands of the metallo-
pMactamases are conserved in glyoxalase II enzymes, suggesting 
that all glyoxalase II enzymes are Zn(II) metalloenzymes. These 
results and their implications are discussed in light of previous 
studies on glyoxalase II, and an active site for the glyoxalase II 
enzymes is proposed. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The glyoxalase system catalyzes the conversion of 2-oxoal-
dehydes into hydroxyacids using two consecutive enzymatic 
reactions, the first of which requires the presence of gluta-
thione [1]. Glyoxalase I is a Zn(II)-containing metalloenzyme 
that catalyzes the isomerization of a hemimercaptal species, 
formed spontaneously from 2-oxoaldehydes and glutathione, 
to form S-(2-hydroxyacyl) glutathione [2]. Methylglyoxal is 
thought to be the principle biological substrate for glyoxalase 
I; it is produced primarily from dihydroxyacetone and glycer-
aldehyde 3-phosphate in glycolysis or from acetone or threo-
nine catabolites [3-5]. The product when glyoxalase I uses 
methylglyoxal as a substrate is 5-D-lactoylglutathione [2]. 
Glyoxalase II catalyzes the hydrolysis of S-D-lactoylgluta-
thione into D-lactate and glutathione [6,7]. The glyoxalase sys-
tem appears to be ubiquitous in nature, appearing in the cy-
tosol and mitochondria of animals and plants, and in bacterial 
cells in high levels [1,3]. The exact physiological role of the 
glyoxalase system is unknown; however, there is some evi-
dence that the system is used to detoxify methylglyoxal and 
other 2-oxoaldehydes, which are cytotoxic and mutagenic by-
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products of lipid and glucose metabolism. There is compelling 
evidence emerging that inhibitors of the glyoxalase system may 
be anti-tumor and anti-malarial agents and may also offer 
treatment to complications associated with diabetes [8-12]. 
Glyoxalase II has been isolated from numerous mammalian 
tissues and from higher plants, and has been partially charac-
terized using biochemical and kinetics studies [6,7,13-21]. 
Chemical modification studies identified evidence for active 
site amine, arginine, and histidine residues [6]. The latter res-
idue has been implicated as a nucleophile which is thought to 
attack the putative activated thiol ester to form an acyl inter-
mediate. The role of an essential histidine is supported by 
sequence comparisons of all glyoxalase II enzymes, which re-
vealed a strictly conserved T-H-X-H-X-D-H motif and two 
other conserved histidines [6,20,21]. Makaroff and coworkers 
have recently noted that the former motif is also present in 
metallo-(3-lactamases [19], which have recently been shown to 
bind 2 moles Zn(II) per mole of enzyme [22,23]. Based on this 
observation, Maiti et al. suggested that glyoxalase II enzymes 
may bind at least one Zn(II) ion [19]. 
Previous biochemical studies had been used to conclude 
that the glyoxalase II enzymes do not bind metal ions 
[6,20,21,24]. Surprisingly though, there is no report, to our 
knowledge, of metal analyses performed on any glyoxalase 
II enzyme. Given the biological roles of the glyoxalase system 
and its involvement in disease, glyoxalase II is an excellent 
target for the generation of rationally designed drugs. How-
ever, detailed structural knowledge of the enzyme is lacking. 
In an effort to directly address whether glyoxalase II is a 
metalloenzyme, the cloned glyoxalase II from A. thaliana was 
purified, kinetically characterized, and analyzed for metal 
ions. We show here that A. thaliana glyoxalase II binds 2 
moles of Zn(II) per mole of enzyme and that glyoxalase II 
may utilize Zn(II) binding motifs similar to those used by the 
metallo-(3-lactamases. Sequence comparisons of glyoxalase II 
from A. thaliana with other glyoxalases suggest that all glyox-
alase II enzymes, like the glyoxalase I enzymes, are Zn(II) 
metalloenzymes. 
2. Materials and methods 
2.1. General 
•S-D-lactoylglutathione was purchased from Sigma. A bicinchonicic 
acid (BCA1) kit was purchased from Pierce Chemical company. All 
chromatographic steps were performed on a Pharmacia FPLC oper-
ating at 4°C. Metal standards were purchased from Fisher and were 
diluted with Nanopure purified FLO. All other chemicals used in this 
study were purchased commercially and were of highest quality avail-
able. 
2.2. Overexpression and purification of glyoxalase II from A. thaliana 
The construction of the overexpression plasmid, pT7-7/GLX2-2, 
has been described previously [19], and this plasmid was used to trans-
form E. coli BL21(DE3)pLysE for overproduction of enzyme. Cul-
tures of these cells were grown at room temperature in ZY media 
containing 200 ug AMP/ml until the cell density measured an 
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ODeoonm of 0.4. Protein production was induced by making the cul-
ture 0.2 mM in IPTG, and the cultures were allowed to shake at room 
temperature for 8 h. The cells were collected by centrifugation, 
washed with multiple additions of ddH 2 0 to remove salt, and lysed 
by a passage through a french press at 16000 psi. Cell debris was 
removed by centrifugation, and the cleared supernatant was loaded 
directly onto a Q-sepharose column, preequilibrated with 10 mM 
MOPS, pH 7.2. Protein was eluted from the column using a linear, 
0-500 mM NaCl gradient, and glyoxalase II eluted at ca. 50 mM 
NaCl. Enzyme purity was assessed by SDS-PAGE and judged to be 
> 90% pure. Glyoxalase II was quantitated using a BCA kit accord-
ing to manufacturer's instructions and by amino acid analysis (Com-
monwealth Biotechnologies, Inc.). Six preparations of the enzyme 
yielded an extinction coefficient of £2go=2.8±0.4 ml/mg-cm. This value 
was used to quantitate enzyme using its absorbance at 280 nm. 
Mass spectra were acquired on a Bruker Reflex II time-of-flight 
(TOF) mass spectrometer operating in the linear mode. Ions were 
produced by matrix-assisted laser desorption ionization (MALDI) 
employing the 355 nm line of a New Wave Research MiniLase-10 
Nd: YAG laser. The matrix solution for MALDI was saturated a-
cyano-4-hydroxycinnamic acid in a solvent system of acetonitrile/ 
water (70/30 v/v) with 0.01% trifluoroacetic acid. The enzyme sample 
solution (11 uJVI) was mixed with the matrix solution at a ratio of 
about 2:5. In order to increase the mass accuracy, bovine serum 
albumin was added to sample solutions as an m/z-calibrate at levels 
of ca. 10~5 M. The [M+2H]2+ and [M+3H]3+ of the calibrant (m/z 
33216 and 22 144, respectively) bracketed the enzyme sample's meas-
ured m/z of 28 767. 
2.3. Metal analyses 
Purified glyoxalase II was dialyzed versus 3 x 1 1 of freshly pre-
pared, chelexed 30 mM MOPS, pH 7.2 at 4°C to remove any loosely 
bound metal ions. Metal analyses were performed on a Varian Induc-
tively Coupled Plasma Emission spectrometer (ICP). Calibration 
curves with 5 standards and correlation coefficients of better than 
0.9999 were used. The final dialysis buffer was used as a blank. Three 
trials of each sample were taken and averaged. The following absorb-
ances for the indicated metal ions were used to ensure the lowest 
detection limit possible: Zn, 213.856 nm; Cu, 324.754 nm; Ni, 
321.604 nm; Co, 238.892 nm; Fe, 259.940 nm; Mn, 257.610 nm; 
and Cd, 228.802 nm. 
2.4. Steady-state kinetics studies 
The activity of glyoxalase II from A. thaliana was assayed by meas-
uring the initial rate of hydrolysis of S-D-lactoylglutathione to yield 
reduced glutathione and D-lactic acid in 30 mM MOPS, pH 7.2 at 
20°C and 37°C using a HP5483 Diode Array UV-Vis Spectrophotom-
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Fig. 1. SDS-PAGE of GLX2-2 purification. Lane 1: Novagen per-
fect protein molecular weight markers, lane 2: boiled cell fraction of 
BL21(DE3) containing pT7-7/GLX2-2 before induction, lane 3: 
boiled cell fraction of BL21(DE3) containing pT7-7/GLX2-2 after 
2 h induction with 0.2 mM IPTG, lane 4: crude protein after french 
press, and lane 5: purified GLX2-2. 
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Fig. 2. MALDI-TOF mass spectrogram of purified GLX2-2. The 
masses of the peaks are: GLX2-2 ([M+H+]+), 28 767 m/z; and bo-
vine serum albumin ([M+2H+]2+, 33216 m/z) and ([M+3H+]3+, 
22144 m/z. The sample was prepared as described in Section 2. 
eter or a Cary IE UV-Vis Spectrophotometer, respectively. The rate 
of hydrolysis was followed by measuring the absorbance at 240 nm 
and by using the molar absorptivity of the substrate (6240 = —3100 
1/mol-cm). The observed hydrolysis rates were corrected for any back-
ground hydrolysis (in the absence of the enzyme) at each substrate 
concentration tested. Substrate concentrations were varied between 15 
and 600 |xM, but concentrations higher than 600 |xM were not used 
due to an observed substrate inhibition. 
3. Results 
3.1. Purification and characterization of glyoxalase II from 
A. thaliana 
Makaroff and coworkers have previously cloned and over-
expressed a cytosolic isozyme of glyoxalase II from A. thaliana 
(GLX2-2); test cultures demonstrated that large quantities of 
both soluble and insoluble glyoxalase II are produced by this 
overexpression system [19]. Since plant glyoxalase II enzymes 
have pi values less than 7 (the cytosolic A. thaliana enzyme 
has a predicted pi of 6.2), an attempt to purify the soluble, 
overexpressed enzyme with Q-sepharose chromatography was 
undertaken. As shown in Fig. 1, glyoxalase II, purified with 
Q-sepharose chromatography, was shown to be >90% pure 
by SDS-PAGE. This purification protocol yielded > 15 mg of 
pure, active glyoxalase II from 1 1 of culture. The N-terminal 
analysis of the purified enzyme revealed the predicted se-
quence of M-K-I-F [19]. Steady-state kinetics studies were 
performed on three different samples of purified GLX2-2 
using S-D-lactoylglutatione as the substrate, and the kcat and 
Km values were 484 ±92 s
_ 1 and 660 ± 100 uM, respectively. 
MALDI-TOF mass spectrometry was used to determine the 
molecular weight of the purified, recombinant glyoxalase II 
from A. thaliana (Fig. 2). The peak at 28 767 m/z is assigned 
as the [M+H]+ peak for GLX2-2. This value represents an 
error of 0.25% in the mass predicted from the DNA sequence 
(predicted value of 28 838 Da). Including the mass of two 
Zn(II) atoms in the predicted mass increases the error to 
0.70%, suggesting that the Zn(II) ions may not remain bound 
during the MALDI process. 
3.2. Metal analyses on recombinant glyoxalase II from 
A. thaliana 
In order to address directly whether glyoxalase II is a met-
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Table 1 
Metal content of glyoxalase II from A. thaliana 
Metal ion Moles metal/mole enzyme 
Zn 
Cu 
Co 
Mn 
Fe 
Ni 
2.1 ±0.5 
< 0.005 
< 0.005 
0.063 ±0.016 
0.41 ±0.24 
0.45 ±0.31 
alloenzyme, metal analyses on the purified enzyme were con-
ducted. After elution from the Q-sepharose column, the en-
zyme was concentrated using an Amicon concentrator with a 
YM-10 membrane and dialyzed versus 3X1 1 of freshly pre-
pared, chelexed 30 mM MOPS, pH 7.2 buffer. As shown in 
Table 1, the only metal ion detectable in significant amounts is 
Zn(II), and the metal to enzyme stoichiometry is 2.1 ±0.5. Six 
additional preparations of the enzyme yielded similar values 
for the metal content of glyoxalase II, even if the dialysis steps 
were left out. This metal content was also unchanged if Zn(II) 
was included in the chromatography buffers at a concentra-
tion of 200 uM. 
Prolonged dialysis of the purified enzyme (2 days at 4°C) 
against 10 mM EDTA in 10 mM MOPS, pH 7.2 resulted in 
precipitation of 90% of the enzyme. The enzyme that did not 
precipitate after EDTA dialysis had no observable activity 
and did not bind any metal ions. We were unable to recon-
stitute enzymatic activity via addition of or dialysis against 
Zn(II). This result suggests that the enzyme that remained in 
solution was irreversibly inactivated, in agreement with pre-
vious metal-reconstitution studies on apo-glyoxalase II [6]. 
Further support for a role of Zn(II) in glyoxalase II comes 
from experiments when GLX2-2 is incubated at pH 7.0 versus 
5 mM EDTA for 2 min before a kinetics assay; the kcat of the 
enzyme dropped by 80%. These experiments clearly show that 
GLX2-2 from A. thaliana tightly binds 2 moles of Zn(II) per 
mole of enzyme and that the presence of Zn(II) is required for 
catalytic activity. Further experiments are necessary to ad-
dress whether the Zn(II) serves a catalytic or a structural 
role in these enzymes. 
4. Discussion 
The observation that glyoxalase II from A. thaliana con-
tains the -H-X-H-X-D- motif which is conserved in the metal-
lo-P-lactamases, lead Makaroff and coworkers to propose that 
glyoxalase II may also bind at least one Zn(II) ion [19]. A 
sequence comparison of three glyoxalase II isozymes from 
A. thaliana (GLX2-1, GLX2-2, and GLX2-3), human glyox-
alase II, two yeast glyoxalase II enzymes (yeast GLOl and 
GL02) with the metal binding regions of the sequenced metal-
lo-p-lactamases reveals a striking homology among these en-
zymes (Fig. 3). All of the ligands to the first Zn(II) site in the 
metallo-P-lactamases (Hisl35, Hisl37, and His201) are strictly 
conserved in the glyoxalase II enzymes. The second Zn(II) site 
in the metallo-P-lactamases contains a His (His272), a Cys 
(Cys225 in all metallo-P-lactamases except the one from 
X. maltophilia which has an aspartic acid [25]), and an Asp 
(Aspl39). Glyoxalase II enzymes contain all of these ligands. 
In addition, the relative spacing between the ligands is also 
conserved (Fig. 3). These observations along with our data 
showing that A. thaliana GLX2-2 binds two moles of Zn(II) 
per mole of enzyme lead us to predict that a dinuclear Zn(II) 
binding site is present in the active site of the glyoxalase II 
enzymes. 
This conclusion contradicts the long held belief that glyox-
alase II enzymes are not metallohydrolases. As recently as this 
year, it was concluded that the cytosolic isozyme of A. thali-
ana glyoxalase II does not depend on metal ions for activity 
[21]. The conclusion that glyoxalase II is not a metalloenzyme 
is based on early biochemical studies on glyoxalase II enzymes 
from various sources. The enzymes from human liver and 
from rat erythrocytes were reported to be inactivated by 
long term exposure to or dialysis against chelating agents, 
such as EDTA, EGTA, 1,10-phenanthroline, and 8-hydroxy-
quinoline; however, the addition of divalent metal ions to the 
dialyzed apoenzyme failed to restore activity [6,24,26]. This 
result was used to conclude that glyoxalase II is not a metal-
loenzyme; however, an equally plausible explanation of these 
early results is that many of the glyoxalase II enzymes are 
irreversibly denatured upon dialysis [7,26] (Crowder, unpub-
lished). In our hands, the addition of Zn(II) to apoGLX2-2 
from A. thaliana also does not yield an active enzyme; our 
inability to restore activity was due to protein precipitation 
during dialysis. The inability to observe reversible metal bind-
ing in a metalloenzyme is not unprecedented; the apo-metallo-
P-lactamase from B. fragilis cannot be reconstituted by addi-
tion of Zn(II) [23]. These earlier studies also reported that 
short incubations of glyoxalase II with EDTA at pHs greater 
than 7.0 did not affect the activities of the enzymes [6,24,26]. 
This result is not surprising because at these slightly basic 
pHs, the metal binding ligands would not be significantly 
protonated, and the lability of the metal ion would be ex-
pected to be low. When A. thaliana GLX2-2 is incubated 
A.t. 
A.t. 
A.t. 
GLX2-1 
GLX2- 2 
GLX2- 3 
HUMAN GLX2 
YEAST GLX2-1 
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A.h. 
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P-LACT 
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ILLSHAHADHAGP 
VIITHAHADRIGG 
FIPNHWHGDCIGG 
SISSHFHSDSTGG 
VINTHYHTDRAGG 
(47) 
(46) 
(44) 
(44) 
(51) 
(51) 
(46) 
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(51) 
(51) 
(50) 
(67) 
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TPGHTQGH 
TPCHTKGH 
TPGHTAGC 
TPCHTSGH 
TPCHTKDS 
TPCHTRDS 
VPGHTRGH 
MAGHTPGS 
GKGHTEDN 
GGGHATDN 
GPGHTPDN 
GPAHTPDG 
(11) 
(15) 
(17) 
(16) 
(15) 
(15) 
(11) 
(17) 
(11) 
(11) 
(11) 
(11) 
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FTGDLI 
FTGDTL 
FTGDAV 
FTGDTL 
FTGDTL 
FTGDTL 
FTGDSL 
ATADSL 
AGGCLV 
FGGCML 
FGGCFI 
YGNCIL 
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CGRENT 
CGHEYT 
PAHDYK 
CGHEYT 
CGHEYT 
PGHEYT 
SGHDYL 
TPHPGA 
TPHPGA 
PGHPDY 
PSHSEV 
GGHSDP 
Fig. 3. Sequence comparison of glyoxalase II enzymes and metallo-P-lactamases in the regi 
tamases. The numbering is based on the sequence of A. thaliana GLX2-1. The numbers 
tween the motifs. The abbreviations of the organisms are: A.t., Arabidopsis thaliana; 
fragilis; S.m., Serratia marcescens; A.h., Aeromonas hydrophila. 
ions of the metal binding ligands of the metallo-p-lac-
in parentheses reflect the number of amino acids be-
R.b., blastica; B.C., Bacillus cereus; B.f., Bacteroides 
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Asp2: 
His, O N 
Asp,; 
His20i 
Fig. 4. Proposed active site of GLX2-2. 
for short times with EDTA at pH 7.0, the activity of the 
enzyme drops by 80%. At this lower pH, the lability of the 
metal ion is expected to be greater. 
Based on (1) our data that demonstrate that A. thaliana 
GLX2-2 binds 2 moles of Zn(II) per mole of enzyme and 
that metal binding is necessary for catalysis, (2) the observa-
tion that all of the ligands associated with the dinuclear Zn(II) 
center of |3-lactamases, as well as their relative positions, are 
conserved in glyoxalase II proteins, and (3) previous biochem-
ical data that identified potential active site residues [6], we 
propose a potential active site model for glyoxalase II. A 
representation of this proposed metallo active site, which is 
based in part on the crystal structure of metallo-(3-lactamase 
from B. fragilis [22] is shown in Fig. 4. The proposed dinu-
clear site has three histidine ligands and a bridging hydroxide 
(or water) binding to the first Zn(II) ion and 1 histidine, 
2 aspartic acids, a bridging hydroxide (or water) and a termi-
nal water bound to the second Zn(II) ion. The crystal struc-
ture of metallo-|3-lactamase from B. fragilis identified an as-
paragine and a lysine that are thought to be involved in 
substrate activation and binding, respectively [22]. Interest-
ingly, previous chemical modification studies identified cata-
lytically important amine and arginine residues [6]. Arginine, 
lysine, and asparagine residues are conserved in most or all of 
the glyoxalase II enzymes identified to date (data not shown). 
This suggests that the metallo-|3-lactamases and glyoxalase II 
enzymes utilize similar reaction mechanisms to perform their 
catalytic functions. 
The use of glyoxalase I inhibitors as anti-tumor and anti-
malarial agents and as a possible intervention in complica-
tions of diabetes has been proposed [3,12]. The inhibition of 
glyoxalase I could result in high cellular levels of methylglyox-
al, which has been shown to be toxic to cells by inhibiting cell 
division, DNA synthesis, and microtubule assembly 
[8,12,27,28]. Glyoxalase I inhibitors demonstrate IC50 concen-
trations of the inhibitor in the micromolar range on cancer 
cell lines [8]. The inability to observe IC50S of sub-micromolar 
concentrations was attributed to the poor penetration of in-
hibitors into the cells [8]. However, the partial removal of 
methylglyoxal from these cells by other means such as diffu-
sion or reaction with aldose reductase cannot be totally dis-
counted [11,29]. 
Glyoxalase II may be a better target for anti-tumor com-
pounds. The putative physiological substrate for glyoxalase II 
is 5-D-lactoylglutathione (SLG), which has been shown to be 
toxic and selective for rapidly proliferating cells, it is involved 
in the inhibition of DNA synthesis [12]. Several thiocarbonate 
and thiocarbonate-carbamate derivatives of glutathione have 
been shown to inhibit glyoxalase II in vitro, and diester ana-
logs of these inhibitors have been shown to be effective on 
cancer cell lines, with IC50 values in the micromolar range 
[9,10,30]. The data presented here along with specific struc-
tural information on the glyoxalase II active site should allow 
us to take a more rational approach to the design of glyox-
alase II inhibitors. Detailed studies on the structure of the 
metal binding site in GLX2-2 and the role of this site in 
catalysis are currently in progress. 
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